RBC cuts target for Globus Medical stock to USD 85.00
Published on 10/08/2026 at 20:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- RBC Capital cut its Globus Medical price target from USD 115.00 to USD 85.00 on October 1, 2026, while retaining an Outperform rating.
- Second-quarter 2026 revenue reached USD 789.61 million, 5.9 percent above the prior-year period and above the USD 782.88 million consensus.
- The Lang & Schwarz price was EUR 65.36 on October 8, 2026 at 8:43 p.m. CEST, down 0.77 percent from EUR 65.87.
Globus Medical stock (ISIN US3795772082) was trading at EUR 65.36 at Lang & Schwarz on October 8, 2026 at 8:43 p.m. CEST, down 0.77 percent versus the prior close of EUR 65.87. On October 1, 2026, RBC Capital lowered its price target for Globus Medical from USD 115.00 to USD 85.00 while retaining an Outperform rating, according to Markets Insider.
Three dated milestones carry numbers
On August 6, 2026, Globus Medical reported second-quarter revenue of USD 789.61 million, up 5.9 percent from the prior-year quarter and above the USD 782.88 million consensus, according to MarketBeat. The comparison places the reported revenue USD 6.73 million, or 0.86 percent, above expectations.
On August 26, 2026, Globus Medical agreed to acquire Higgs Boson Health to expand AI-driven digital solutions, a transaction listed by Simply Wall St. The company profile identifies 6,000 full-time employees and a business spanning spine, orthopedic trauma, joint reconstruction and surgical technologies.
On October 1, 2026, RBC Capital reduced its target by USD 30.00, equivalent to a 26.09 percent cut from USD 115.00. The cited rationale included second-half caution in two business areas and volatility in spine demand, according to Markets Insider.
What does the target cut imply?
RBC's revised USD 85.00 target remains USD 20.00 above its reduced level of USD 65.00 in the US market context, but the target itself is denominated in US dollars and cannot be netted against the EUR 65.36 Lang & Schwarz quote. The sharper signal is the change in the analyst view: the rating stayed Outperform while the target fell 26.09 percent.
The next reporting date is estimated
MarketBeat lists November 5, 2026 as the estimated date for Globus Medical's third-quarter results. The latest completed quarter provides the measurable operating reference: revenue of USD 789.61 million and a 5.9 percent year-over-year increase.
EUR 65.36 after the Xetra close
The Lang & Schwarz quote stood at EUR 65.36 on October 8, 2026 at 8:43 p.m. CEST in after-hours trading, down 0.77 percent versus the prior close of EUR 65.87. The finance quote for the NYSE listing showed USD 73.33 at 2:48 p.m. EDT on the same date, separating the US-market reference from the German euro quote.
The further course of trading is shown by the continuously updated real-time quote of Globus Medical stock.
Globus Medical stock facts
- Company: Globus Medical, Inc.
- ISIN: US3795772082
- Ticker: GMED
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 8, 2026, 8:43 p.m. CEST): EUR 65.36
- Change versus prior close: minus 0.77 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 65.87
- Market capitalization: USD 9.9 billion (as of October 8, 2026)
- Sector / Industry: Healthcare / Medical Devices
Market context: Market report S&P 500.
